Astrazeneca Phar
₹5,970.5+33.50 (+0.56%)as of 2026-10-16
- Market Cap
- ₹14,866Cr.
- P/E Ratio
- 85.7
- P/B Ratio
- 17.11
- EPS (TTM)
- ₹69.67
- Day Range
- ₹5,843.5 – ₹6,009
- Div Yield
- 0.61%
- ROCE
- 29.3%
- ROE
- 23.3%
52W Low: ₹5,64052W High: ₹9,850
Themes:💊 Pharma & CDMO
Descriptive screens built from published data — not investment advice.
At a glance
- Sales have grown 31.0% a year over three years.
- Debt is 0.13× its shareholders’ equity.
From reported financials and exchange prices. Descriptive only, not advice.
Astrazeneca_Phar — Price
Interval
Style
Failed: 503
Evenstocks Score
Middle third
Overall
Valuation
Quality
Fundamental
Growth
Investment Checklist
Quick assessment based on key parametersPerformance
N/ATrailing return unavailableValuation
P/E 85.7P/E: 85.7 | P/B: 17.11Growth
GrowingSales CAGR — 3Y: 31% · 1Y: 31%Profitability
High MarginROCE: 29.3% | ROE: 23.3%Key Metrics
Valuation
PEG Ratio 5.71
Price / Sales 6.11x
Book Value ₹349
Margins & returns
Operating Margin 9%
Net Margin 7.0%
Return on Assets 8.6%